全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations

DOI: 10.1155/2013/839456

Full-Text   Cite this paper   Add to My Lib

Abstract:

Purpose. To determine if the use of a novel vancomycin nomogram predicts dosing regimens that achieve target trough concentrations equal to or more accurate than dosing regimens calculated using traditional pharmacokinetic calculations, evaluate the incidence of subtherapeutic and supratherapeutic troughs, and assess pharmacist's impressions of the nomogram. Methods. Prospective, open-label study in 473 patients who had a new order for vancomycin and were >18 years of age and ≤120?kg. Patients were randomized to the active group, dosed using the nomogram, or to the control group, dosed using traditional pharmacokinetic calculations already in place at our institution. Results. Patients dosed via nomogram were within the appropriate trough range in 44% of cases compared to 33% in the control group ( ). Vancomycin troughs less than 10?mcg/mL were significantly decreased with the use of nomogram ( ). Incidence of supratherapeutic troughs, greater than 20?mcg/mL, was not significantly different between groups ( ), and pharmacists agreed that the nomogram was easy to use and saved their time. Conclusions. A novel vancomycin nomogram was prospectively validated and found to be more effective than traditional pharmacokinetic dosing. The nomogram is being implemented as the standard dosing protocol at our institution. 1. Introduction Vancomycin is a glycopeptide antibiotic used to treat infections caused by gram-positive organisms, most commonly methicillin-resistant Staphylococcus aureus (MRSA). It is used for a variety of infections including cellulitis, pneumonia, sepsis, and endocarditis [1]. Due to potential side effects such as nephrotoxicity, ototoxicity, and the potential for bacterial resistance with low troughs, vancomycin concentrations are routinely monitored to ensure appropriate dosing. Previously, appropriate trough concentrations were considered to be between 5–15?mcg/mL [2, 3]. However, due to the emergence of vancomycin resistance, recommended trough concentrations have increased. In 2009, the American Society of Health-System Pharmacists/Infectious Diseases Society of America/Society of Infectious Diseases Pharmacists published a consensus statement, updating the guidelines for appropriate vancomycin trough concentrations [2]. These guidelines recommend that troughs should remain above 10?mcg/mL at all times to limit treatment failures and resistance. For patients being treated for severe infections such as, bacteremia, endocarditis, meningitis, MRSA pneumonia, osteomyelitis, or sepsis, trough concentrations should be maintained between 15

References

[1]  Vancomycin. Clinical Pharmacology 2000, Gold Standard Multimedia, 2010.
[2]  M. J. Rybak, B. Lomaestro, J. C. Rotschafer et al., “Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists,” American Journal of Health-System Pharmacy, vol. 66, no. 1, pp. 82–98, 2009.
[3]  J. E. Geraci, “Vancomycin,” Mayo Clinic Proceedings, vol. 52, no. 10, pp. 631–634, 1977.
[4]  C. Liu and H. F. Chambers, “Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 10, pp. 3040–3045, 2003.
[5]  G. R. Matzke, R. W. McGory, C. E. Halstenson, and W. F. Keane, “Pharmacokinetics of vancomycin in patients with various degrees of renal function,” Antimicrobial Agents and Chemotherapy, vol. 25, no. 4, pp. 433–437, 1984.
[6]  R. C. Moellering Jr., D. J. Krogstad, and D. J. Greenblatt, “Vancomycin therapy in patients with impaired renal function: a nomogram for dosage,” Annals of Internal Medicine, vol. 94, no. 3, pp. 343–346, 1981.
[7]  J. C. Rotschafer, K. Crossley, D. E. Zaske, et al., “Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations,” Antimicrobial Agents and Chemotherapy, vol. 22, no. 3, pp. 391–394, 1982.
[8]  K. D. Lake and C. D. Peterson, “A simplified dosing method for initiating vancomycin therapy,” Pharmacotherapy, vol. 5, no. 6, pp. 340–344, 1985.
[9]  H. E. Nielsen, H. E. Hansen, B. Korsager, and P. E. Skov, “Renal excretion of vancomycin in kidney disease,” Acta Medica Scandinavica, vol. 197, no. 4, pp. 261–264, 1975.
[10]  R. Kullar, S. N. Leonard, S. L. Davis et al., “Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15–20?mg/L suggested by the vancomycin consensus guidelines,” Pharmacotherapy, vol. 31, no. 5, pp. 441–448, 2011.
[11]  S. Devabhakthumi, J. P. Gonzales, A. L. Tata, et al., “Evaluation of vancomycin dosing and monitoring in adult medicine patients,” Hospital Pharmacy, vol. 47, no. 6, pp. 451–459, 2012.
[12]  R. Thalakada, M. Legal, T. T. Y. Lau, T. Luey, J. Batterink, and M. H. H. Ensom, “Development and validation of a novel vancomycin dosing nomogram for achieving high-target trough levels at 2 Canadian teaching hospitals,” The Canadian Journal of Hospital Pharmacy, vol. 65, no. 3, pp. 180–187, 2012.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133